Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL-1 genotypes may confer risk for Alzheimer's disease through IL-1 overexpression and IL-1-driven neurodegenerative cascades.
|
10716257 |
2000 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL-1 has a number of actions relevant to Alzheimer's disease, including excessive expression of neuronal Abeta precursor protein and other plaque-associated proteins, and induction of astrocyte activation and astrocytic overexpression of S100B.
|
11754997 |
2002 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL-1 upregulates betaAPP and S100B expression and drives numerous neurodegenerative and self-amplifying cascades that support a neuroinflammatory component in the pathogenesis of sporadic and Down syndrome-related Alzheimer disease.
|
15290893 |
2004 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-1 beta (IL-1beta) gene, especially beta2 polymorphism, is frequently observed in Alzheimer's disease, a remarkable degenerative state in which HI is among the known risk factors.
|
15891809 |
2005 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interleukin-1β is a potent proinflammatory cytokine that plays a key role in the pathogenesis of the brain aging and diverse range of neurological diseases including Alzheimer's disease, Parkinson's disease, stroke and persistent pain.
|
31535638 |
2020 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
A higher level of M2 markers (Arg-1, MRC1/CD206) and a lower level of classic M1 markers (TNFa, IL-1β) were obtained in Aβ-pretreated N9 cells with chitinase1, suggesting that chitinase1 polarized the microglia into an anti-AD M2 phenotype.
|
28499970 |
2017 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
A number of genetic risk factors have been identified for Alzheimer's disease (AD) including genes involved in the inflammatory response (interleukin 1A, [IL-1α (-889)], interleukin 1B (IL-1β [+3953]), and tumor necrosis factor (TNF [-308 and -850]).
|
20961668 |
2012 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Age-associated increases in microglial activation and IL-1 expression may contribute to the age-associated increased risk of Alzheimer's disease.
|
9542587 |
1998 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Aggravation of Alzheimer's disease due to the COX-2-mediated reciprocal regulation of IL-1β and Aβ between glial and neuron cells.
|
24621265 |
2014 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
RGD |
Akebia Saponin D attenuates amyloid β-induced cognitive deficits and inflammatory response in rats: involvement of Akt/NF-κB pathway.
|
22963993 |
2012 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As further evidence of the importance of IL-1 in Alzheimer pathogenesis, two new genetic studies of inheritance of specific polymorphisms in IL-1 genes in Alzheimer and control patients show that homozygosity for a specific IL-1A gene polymorphism at least triples risk for development of Alzheimer's disease.
|
10959036 |
2000 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
As these patients are at higher risk of conversion to dementia, we propose that an increased serum IL-1beta level is a stage marker of the ongoing brain neurodegeneration in the continuum between normal ageing and AD.
|
19996595 |
2009 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease.
|
14681913 |
2004 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
CTD_human |
Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis.
|
18675847 |
2008 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis.
|
18675847 |
2008 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Because there is increasing interest in the common disruption of cytokine pathways seen in both AD and schizophrenia, we tested the association between the functional interleukin-1beta -511 promoter polymorphism with delusions and hallucinations in AD.
|
15236409 |
2004 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Because there is increasing interest in the common disruption of cytokine pathways seen in both AD and schizophrenia, we tested the association between the functional interleukin-1beta -511 promoter polymorphism with delusions and hallucinations in AD.
|
15236409 |
2004 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Brain inflammation including increases in inflammatory cytokines such as IL-1β is widely believed to contribute to the pathophysiology of Alzheimer's disease.
|
29712570 |
2018 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
CCH strongly enhanced NLRP3, activated caspase-1 and IL-1β expressions in hippocampus and thalamus at age 12 M of AD mice.
|
29885344 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Circulating levels of IL-1 family cytokines and receptors in Alzheimer's disease: new markers of disease progression?
|
30541566 |
2018 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared to IL1β-induced inflammation, HC have increased CD14 levels after vitamin D treatment (p<0.001), whereas the IL1β-induced CD14 expression of AD patients' monocytes did not change after vitamin D treatment (p=0.8).
|
28765037 |
2018 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Compared to the IL-1β CC genotype (-31), the TT genotype significantly increased the risk of AD (TT vs. CC, adjusted OR = 1.72, 95% CI = 1.13-2.61, p = 0.010).
|
26937653 |
2016 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compared with controls, IL-1β (pooled SMD: 1.37, 95% CI: 0.06-2.68, significant heterogeneity: I<sup>2</sup> = 96.01%) was significantly elevated in Alzheimer's disease.
|
30104698 |
2018 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with the sham operation group, the spatial learning and memory abilities of AD rats were signifificantly decreased (P<0.05 or P<0.01; Expressions of IL-1, TNF-α, Aβ and apoptosis-signaling proteins caspase-3, -8, -9, -12 were signifificantly up-regulated (P<0.05 or P<0.01).
|
27022730 |
2017 |